David Hui1, Zoe M Weinstein2, Debbie M Cheng3, Emily Quinn4, Hyunjoong Kim5, Colleen Labelle6, Jeffrey H Samet7. 1. Boston University School of Medicine, 72 East Concord St., Boston, MA 02118, United States. Electronic address: davidhui@bu.edu. 2. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, United States. Electronic address: zoe.weinstein@bmc.org. 3. Boston University School of Public Health, Department of Biostatistics, 801 Massachusetts Avenue, 3rd Floor, Boston, MA 02118, United States. Electronic address: dmcheng@bu.edu. 4. Boston University School of Public Health, Data Coordinating Center, 85 East Newton St, M921, Boston, MA 02118, United States. Electronic address: eq@bu.edu. 5. Boston University School of Medicine, 72 East Concord St., Boston, MA 02118, United States. Electronic address: hjk2@bu.edu. 6. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, United States. Electronic address: colleen.labelle@bmc.org. 7. Boston University School of Medicine/Boston Medical Center, Department of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education (CARE) Unit, 801 Massachusetts Avenue, 2nd Floor, Boston, MA 02118, United States; Boston University School of Public Health, Department of Community Health Sciences, 801 Massachusetts Avenue, 4th Floor, Boston, MA 02118, United States. Electronic address: jsamet@bu.edu.
Abstract
INTRODUCTION: Patients with opioid use disorder often require multiple treatment attempts before achieving stable recovery. Rates of disengagement from buprenorphine are highest in the first month of treatment and termination of buprenorphine therapy results in return to use rates as high as 90%. To better characterize these at-risk patients, this study aims to describe: 1) the frequency and characteristics of patients with very early disengagement (≤1month) from Office Based Opioid Treatment (OBOT) with buprenorphine and 2) the frequency and characteristics of patients who re-engage in care at this same OBOT clinic within 2years, among the subset of very early disengagers. METHODS: This is a retrospective cohort study of adult patients enrolled in a large urban OBOT program. Descriptive statistics were used to characterize the sample and the proportion of patients with very early (≤1month) disengagement and their re-engagement. Multivariable logistic regression models were used to identify patient characteristics associated with the outcomes of very early disengagement and re-engagement. Potential predictors included: sex, age, race/ethnicity, education, employment, opioid use history, prior substance use treatments, urine drug testing, and psychiatric diagnoses. RESULTS: Overall, very early disengagement was unusual, with only 8.4% (104/1234) of patients disengaging within the first month. Among the subset of very early disengagers with 2years of follow-up, the proportion who re-engaged with this OBOT program in the subsequent 2years was 11.9% (10/84). Urine drug test positive for opiates within the first month (AOR: 2.01, 95% CI: 1.02-3.93) was associated with increased odds of very early disengagement. Transferring from another buprenorphine prescriber (AOR: 0.09, 95% CI: 0.01-0.70) was associated with decreased odds of very early disengagement. No characteristics were significantly associated with re-engagement. CONCLUSIONS: Early disengagement is uncommon; however, continued opioid use appeared to be associated with higher odds of treatment disengagement and these patients may warrant additional support. Re-engagement was uncommon, suggesting the need for a more formal explicit system to encourage and facilitate re-engagement among patients who disengage.
INTRODUCTION:Patients with opioid use disorder often require multiple treatment attempts before achieving stable recovery. Rates of disengagement from buprenorphine are highest in the first month of treatment and termination of buprenorphine therapy results in return to use rates as high as 90%. To better characterize these at-risk patients, this study aims to describe: 1) the frequency and characteristics of patients with very early disengagement (≤1month) from Office Based Opioid Treatment (OBOT) with buprenorphine and 2) the frequency and characteristics of patients who re-engage in care at this same OBOT clinic within 2years, among the subset of very early disengagers. METHODS: This is a retrospective cohort study of adult patients enrolled in a large urban OBOT program. Descriptive statistics were used to characterize the sample and the proportion of patients with very early (≤1month) disengagement and their re-engagement. Multivariable logistic regression models were used to identify patient characteristics associated with the outcomes of very early disengagement and re-engagement. Potential predictors included: sex, age, race/ethnicity, education, employment, opioid use history, prior substance use treatments, urine drug testing, and psychiatric diagnoses. RESULTS: Overall, very early disengagement was unusual, with only 8.4% (104/1234) of patients disengaging within the first month. Among the subset of very early disengagers with 2years of follow-up, the proportion who re-engaged with this OBOT program in the subsequent 2years was 11.9% (10/84). Urine drug test positive for opiates within the first month (AOR: 2.01, 95% CI: 1.02-3.93) was associated with increased odds of very early disengagement. Transferring from another buprenorphine prescriber (AOR: 0.09, 95% CI: 0.01-0.70) was associated with decreased odds of very early disengagement. No characteristics were significantly associated with re-engagement. CONCLUSIONS: Early disengagement is uncommon; however, continued opioid use appeared to be associated with higher odds of treatment disengagement and these patients may warrant additional support. Re-engagement was uncommon, suggesting the need for a more formal explicit system to encourage and facilitate re-engagement among patients who disengage.
Authors: Yoichiro Takayanagi; Adam P Spira; Kimberly B Roth; Joseph J Gallo; William W Eaton; Ramin Mojtabai Journal: JAMA Psychiatry Date: 2014-03 Impact factor: 21.596
Authors: Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham Journal: J Subst Abuse Treat Date: 2010-07
Authors: Cindy Parks Thomas; Deborah W Garnick; Constance M Horgan; Kay Miller; Alex H S Harris; Melissa M Rosen Journal: J Subst Abuse Treat Date: 2013-03-13
Authors: Marina Davoli; Anna M Bargagli; Carlo A Perucci; Patrizia Schifano; Valeria Belleudi; Matthew Hickman; Giuseppe Salamina; Roberto Diecidue; Federica Vigna-Taglianti; Fabrizio Faggiano Journal: Addiction Date: 2007-12 Impact factor: 6.526
Authors: Courtney L Breen; Simon J Harris; Nicholas Lintzeris; Richard P Mattick; Lynn Hawken; James Bell; Alison J Ritter; Michael Lenné; Elizabeth Mendoza Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Sarah M Bagley; Scott E Hadland; Samantha F Schoenberger; Mam Jarra Gai; Deric Topp; Eliza Hallett; Erin Ashe; Jeffrey H Samet; Alexander Y Walley Journal: J Subst Abuse Treat Date: 2021-03-23
Authors: William C Becker; Erin E Krebs; Sara N Edmond; Lewei A Lin; Mark D Sullivan; Roger D Weiss; Adam J Gordon Journal: J Gen Intern Med Date: 2020-11-03 Impact factor: 5.128
Authors: Morgane Guillou-Landreat; Philippe Levassor; Marylène Guerlais; Veronique Sebille; Caroline Victorri-Vigneau Journal: Int J Environ Res Public Health Date: 2021-05-27 Impact factor: 3.390